AVM Biotechnology is a clinical stage company advancing its small molecule, AVM0703, in a Phase I/II clinical trial in patients with relapsed/refractory (R/R) no-option Non-Hodgkin’s Lymphoma/Leukemia (NHL). Led by a strong executive leadership team and global scientific advisory board, the company is planning for accelerated FDA approval in Acute Lymphoblastic Leukemia (ALL), a patient subset of NHL, and a commercial launch in mid-2024. Additionally, preclinical data suggests potential applications in solid tumors and autoimmune diseases. AVM has been awarded three Phase I NIH Small Business Innovation Research grants by the National Cancer Institute (NCI) and National Institute of Diabetes and Kidney Disease (NIDDK) as well as two Phase II grants from the same agencies. The company holds eight worldwide patent families directed to AVM0703 and has developed a robust and proprietary patenting strategy resulting in granted claims and patent protection that should extend to 2040. In a single, one-hour outpatient infusion, AVM0703 rapidly induces, expands, and mobilizes endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cells by a glucocorticoid-receptor-independent mechanism. Durable Clinical Response has been achieved in R/R NHL/Leukemia including T-cell Lymphoma to at least 9 months with favorable safety results. AVM0703 also potentiates chemotherapy and CAR-T response in pre-clinical models.